'Double blind, you are the weakest link--good-bye!'

Devereaux, P. J.; Bhandari, Mohit; Montori, Victor M.; Manns, Braden J.; Ghali, William A.; Guyatt, Gordon H.
January 2002
ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, pA-11
Academic Journal
Editorial. Advocates the abandonment of the phrase double blind, which is used as a marker of validity of a randomized controlled trial (RCT), and recommends transparent reporting of the blinding status of each group involved in a clinical trial. Information on blinding in RCT; Example of the use of blinding in scientific experimentation; Groups who can potentially introduce bias into an RCT.


Related Articles

  • The pursuit of unbiased research: randomized controlled trials. Schulz, Kenneth F. // Contemporary OB/GYN;Feb2000, Vol. 45 Issue 2, p48 

    Focuses on randomized controlled trial in medical research. Discussion on randomization; Benefits of randomization; Nonrandomized comparisons and bias.

  • Writing for CIM--help for authors.  // Clinical & Investigative Medicine;Oct2003, Vol. 26 Issue 5, p227 

    Provides information on the submission of research and review articles and editorial commentaries on any subject related to clinical medicine and the requirements for such articles of the journal "Clinical and Investigative Medicine."

  • The 'n = 1' randomized controlled trial. Miller, Mary G; Corner, Jessica // Palliative Medicine;1999, Vol. 13 Issue 3, p255 

    Discusses how results from `n=1' studies in different patients can be combined to allow a more general conclusion about patient responses to treatment. Difficulties associated with both the traditional `trial of therapy' and randomized controlled trials; Possible bias in the `trial of therapy';...

  • Determination of the Clinical Importance of Study Results. Man-Son-Hing, Malcolm; Laupacis, Andreas; O'Rourke, Keith; Molnar, Frank J.; Mahon, Jeffery; Chan, Karen B. Y.; Wells, George // JGIM: Journal of General Internal Medicine;Jun2002, Vol. 17 Issue 6, p469 

    Formal statistical methods for analyzing clinical trial data are widely accepted by the medical community. Unfortunately, the interpretation and reporting of trial results from the perspective of clinical importance has not received similar emphasis. This imbalance promotes the historical...

  • Work Practice Guides. Zehrer, Cindy // Applied Clinical Trials;May2001, Vol. 10 Issue 5, p70 

    Focuses on work practice guides in clinical research. Promotion of clinical research best practices; Fostering of consistency within the clinical group.

  • Notes from the field. Hellsten, Donna // Applied Clinical Trials;May2001, Vol. 10 Issue 5, p78 

    Focuses on the use of computers in clinical research. Electronic data capture; Questions to ask prospective vendors.

  • From the Publisher. Blow, Wayne K. // Applied Clinical Trials;Feb2011 eClinial Trials Supplement, p4 

    The article provides information about the contents of "eClinical Trials" including the articles on various aspects of clinical trials technology and a eClinical Trials Directory that offers the up-to-date contact information on the industry's vendors.

  • Baseline imbalance in randomized controlled trials. Roberts, Chris; Torgerson, David // BMJ: British Medical Journal (International Edition);07/17/99, Vol. 319 Issue 7203, p185 

    Focuses on the imbalances in baseline characteristics of randomized controlled clinical trials. Recommendation on how to report clinical trials; Proposed strategy on how to adust for baseline variables; Possibilities of chance bias.

  • The Importance of Clinical Trials. Jones, Walt // Total Health;Jul/Aug99, Vol. 21 Issue 3, p14 

    Discusses the significance of clinical trials. Benefits of clinical trials; Questions regarding product effectiveness; Product use consideration.

  • Time to register randomised trials. Horton, Richard; Smith, Richard // BMJ: British Medical Journal (International Edition);10/02/99, Vol. 319 Issue 7214, p865 

    Advocates the registration of randomized clinical trials. History of the effort to register randomized trials; Organizations that will hold a joint conference to promote the registration of trials; Financial investments in randomized controlled trials; Consequences of the failure to register all...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics